U.S. markets open in 5 hours 24 minutes

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1300-0.0900 (-7.38%)
At close: 4:00PM EST

1.1700 +0.04 (3.54%)
Pre-Market: 4:06AM EST

InVivo Therapeutics Holdings Corp.

One Kendall Square
Suite B14402
Cambridge, MA 02139
United States
617 863 5500

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard M. ToselliPres, CEO, Chief Medical Officer & Director1.22MN/A1958
Mr. Richard C. ChristopherCFO & Treasurer553.07kN/A1970
Dr. Robert S. Langer Jr.Co-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Joseph Philip VacantiCo-FounderN/AN/A1949
Mr. William D'Agostino PESr. VP of OperationsN/AN/AN/A
Ms. Heather HamelVP of Legal Affairs & Bus. Devel. and Corp. Sec.N/AN/AN/A
Dr. Louis VaickusConsultantN/AN/A1953
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.